Search clinical trials for: RAD011

Total 362 results

Radius Pharmaceuticals, Inc.

Withdrawn

A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome
Radius Pharmaceuticals, Inc.

Terminated

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome (SCOUT-015)

Prader-Willi Syndrome

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC)

Germany
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Tuberous Sclerosis | Angiolipoma

United States
Novartis Pharmaceuticals

Completed

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Hodgkin Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... and other collaborators

Completed

Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (NFC-RAD001)

Glioma

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (RTOG 0913)

Brain and Central Nervous System Tumors

United States, Israel, Canada
Guangdong Provincial People's Hospital
Novartis

Unknown

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Neuroendocrine Tumors | Carcinoid Tumor

China
Peking University People's Hospital
Cellular Biomedicine Group Ltd.

Unknown

C-CAR011 Treatment in Subjects With ALL After HSCT

Acute Lymphoblastic Leukemia(ALL)

China
University of Chicago
Novartis Pharmaceuticals

Terminated

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC (RAD001)

Non-Small Cell Lung Cancer

United States
St. James's Hospital, Ireland
Royal College of Surgeons, Ireland

Not yet recruiting

RADA16 for Reducing Drain Output Trajectory Following Neck Dissection (ROUND)

Head and Neck Cancer
Fox Chase Cancer Center

Recruiting

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Metastatic Pancreatic Cancer

United States
University of Michigan
Institut Rosell

Completed

Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis

Chronic Rhinosinusitis
Novartis Pharmaceuticals

Terminated

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Spain, Korea, Republic of, Netherlands, Taiwan
3D Medicines (Beijing) Co., Ltd.

Withdrawn

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China
ActoGeniX N.V.

Completed

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

Moderately Active Ulcerative Colitis

Canada, Netherlands, Sweden, Belgium
Anne Beaven, MD
Novartis

Terminated

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United States
Northwestern University

Not yet recruiting

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Cutaneous T Cell Lymphoma

United States
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
Southern Europe New Drug Organization
Bayer; Novartis

Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Advanced Solid Tumors

Italy
Radiopharm Theranostics, Ltd

Recruiting

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

Healthy Volunteers | Pancreatic Ductal Adenocarcinoma

United States
Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Completed

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Novartis Pharmaceuticals

Completed

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Carcinoma

United States
Novartis Pharmaceuticals

Completed

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (MACS0460)

Adenocarcinoma | Carcinoma | Renal Cell | Non Clear Cell Renal Carcinoma | Papillary Cell Renal Carcinoma

France, Italy, Belgium, Germany, Spain, Poland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (\MACS1304)

Lung Neuroendocrine Neoplasm

China
Ratchavithi Hospital

Unknown

Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma (CRAD001T)

Cholangiocarcinoma
Novartis Pharmaceuticals

Completed

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Lymphangioleiomyomatosis

France, United States, Italy
NYU Langone Health

Completed

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Neurofibromatosis Type 2 | Meningiomas | Vestibular Schwannomas

United States
Novartis Pharmaceuticals

Completed

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Renal Cell Carcinoma

South Africa, Egypt, Saudi Arabia, Russian Federation, Lebanon, Thailand, Jordan, India, Tunisia, Algeria
Seoul National University Hospital

Completed

Study of RAD001 in Adenoid Cystic Carcinoma (ACCRAD001)

Adenoid Cystic Carcinoma

Korea, Republic of
Austin Health

Unknown

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol (RADiChol)

Cholangiocarcinoma

Australia
Sheba Medical Center

Unknown

Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

Prostate Cancer

Israel
Krankenhaus Nordwest

Completed

Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction (S387)

Advanced Gastric Cancer | Advanced Cancer of the Esophagogastric Junction

Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy (PILLAR-1)

Lymphoma, Mantle- Cell

United States
Novartis Pharmaceuticals

Completed

Treatment of Patients With RAD001 With Progressive Sarcoma

Progressive Sarcoma

Germany, Italy
Emory University

Completed

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD-4)

Metastatic Renal Cell Carcinoma

China, Argentina, Brazil, Russian Federation, Bulgaria, United States
The Methodist Hospital Research Institute
Novartis

Completed

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer (RAD001)

Carcinoma, Renal Cell

United States
Daniel George, MD
Novartis Pharmaceuticals

Completed

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center

Completed

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Asan Medical Center
Novartis

Completed

RAD001 in Advanced Sarcoma

Soft Tissue Sarcomas | Bone Sarcomas

Korea, Republic of
Novartis Pharmaceuticals

Completed

Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

Non Small Cell Lung Cancer

Australia, Germany, United States
Cliniques universitaires Saint-Luc- Université...

Completed

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Transitional Cell Carcinoma

Belgium
Swedish Medical Center
Novartis

Completed

Phase II Trial of RAD001 in Refractory Colorectal Cancer

Colorectal Cancer

United States
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR)

Breast Cancer | Triple Negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma

China
Asan Medical Center

Completed

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Stomach Neoplasm

Korea, Republic of
Hellenic Cooperative Oncology Group
Novartis

Terminated

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Gastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine Tumors

Greece
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Israel

Search clinical trials for: RAD011

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations